BR9611367A - Formulação farmacêutic liofilizada estável - Google Patents

Formulação farmacêutic liofilizada estável

Info

Publication number
BR9611367A
BR9611367A BR9611367A BR9611367A BR9611367A BR 9611367 A BR9611367 A BR 9611367A BR 9611367 A BR9611367 A BR 9611367A BR 9611367 A BR9611367 A BR 9611367A BR 9611367 A BR9611367 A BR 9611367A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
lyophilized pharmaceutical
stable lyophilized
stable
formulation
Prior art date
Application number
BR9611367A
Other languages
English (en)
Inventor
Laurence Colliere
Colette Bouloumie
Philippe Faure
Thierry Breul
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9484220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9611367A publication Critical patent/BR9611367A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9611367A 1995-11-03 1996-10-30 Formulação farmacêutic liofilizada estável BR9611367A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9513022A FR2740686B1 (fr) 1995-11-03 1995-11-03 Formulation pharmaceutique lyophilisee stable
PCT/FR1996/001706 WO1997017064A1 (fr) 1995-11-03 1996-10-30 Formulation pharmaceutique lyophilisee stable

Publications (1)

Publication Number Publication Date
BR9611367A true BR9611367A (pt) 1999-02-23

Family

ID=9484220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611367A BR9611367A (pt) 1995-11-03 1996-10-30 Formulação farmacêutic liofilizada estável

Country Status (32)

Country Link
US (1) US6284277B1 (pt)
EP (1) EP0858325B1 (pt)
JP (1) JP3357376B2 (pt)
KR (1) KR100367752B1 (pt)
CN (1) CN1124844C (pt)
AR (1) AR004255A1 (pt)
AT (1) ATE221374T1 (pt)
AU (1) AU713383B2 (pt)
BR (1) BR9611367A (pt)
CA (1) CA2234140C (pt)
CZ (1) CZ287178B6 (pt)
DE (1) DE69622735T2 (pt)
DK (1) DK0858325T3 (pt)
EE (1) EE04293B1 (pt)
ES (1) ES2180805T3 (pt)
FR (1) FR2740686B1 (pt)
HK (1) HK1015697A1 (pt)
IL (1) IL124214A (pt)
IS (1) IS1967B (pt)
MX (1) MX9803344A (pt)
MY (1) MY116578A (pt)
NO (1) NO322582B1 (pt)
NZ (1) NZ321616A (pt)
PL (1) PL186284B1 (pt)
PT (1) PT858325E (pt)
RU (1) RU2163801C2 (pt)
SK (1) SK283031B6 (pt)
TR (1) TR199800782T2 (pt)
TW (1) TW442295B (pt)
UA (1) UA60297C2 (pt)
WO (1) WO1997017064A1 (pt)
ZA (1) ZA969176B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US6197787B1 (en) * 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
JP4939680B2 (ja) * 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
DE19754324A1 (de) * 1997-12-08 1999-06-10 Byk Gulden Lomberg Chem Fab Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
EE04576B1 (et) 1997-12-08 2006-02-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
FR2781227B1 (fr) * 1998-07-20 2002-02-22 Sanofi Sa Procede pour la preparation du sel potassique du lintitript
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
US6898762B2 (en) 1998-08-21 2005-05-24 United Video Properties, Inc. Client-server electronic program guide
FR2787329B1 (fr) * 1998-12-17 2001-02-09 Aventis Pharma Sa Nouvelle application therapeutique des heparines de bas poids moleculaire
AU772633B2 (en) * 1999-03-03 2004-05-06 Eli Lilly And Company Echinocandin/carbohydrate complexes
ES2433678T3 (es) * 1999-03-03 2013-12-12 Eli Lilly & Company Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas
FR2793685B1 (fr) * 1999-05-19 2001-08-24 Promindus Actions Promotionnel Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
FR2805539B1 (fr) * 2000-02-25 2005-06-10 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indolizine et procede de teinture
US6716884B1 (en) 2000-05-19 2004-04-06 Promindus (Actions Promotionnelles Dans L'industrie Et Le Commerce) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
EP1310252A4 (en) * 2000-08-18 2009-06-10 Takeda Pharmaceutical INJECTIONS
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20040039036A1 (en) * 2000-11-24 2004-02-26 Yoshimi Hashimoto Water-soluble liquid internal medicine
MXPA04004657A (es) * 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
EP1453826A1 (en) * 2001-12-10 2004-09-08 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-[[2-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4'] non-1-en-4-one
PL205936B1 (pl) 2002-02-22 2010-06-30 Schering Corp Farmaceutyczny preparat zawierający termozolomid oraz sposób jego wytwarzania
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
BR0315047A (pt) 2002-10-03 2005-08-23 Hoffmann La Roche Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
TWI284124B (en) * 2002-12-03 2007-07-21 Hoffmann La Roche Aminoalkoxyindoles
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
WO2004098614A1 (ja) * 2003-05-07 2004-11-18 Eisai Co., Ltd. メチルコバラミン含有凍結乾燥製剤及びその製造方法
JP2007504177A (ja) * 2003-09-02 2007-03-01 プリヴァ−ラケマ，エー．エス． 医薬組成物、その製造方法及び治療上の使用
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
US20050255161A1 (en) * 2004-05-10 2005-11-17 Servet Buyuktimkin Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US20060275331A1 (en) * 2004-08-31 2006-12-07 Borek Zaludek Pharmaceutical composition, method of manufacturing and therapeutic use thereof
ES2441718T3 (es) * 2004-11-02 2014-02-06 Northwestern University Compuestos de piridazina, composiciones y métodos
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1787641A1 (de) * 2005-11-22 2007-05-23 Helm AG Tazobactam-Piperacillin-Lyophilisat
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
WO2007103711A2 (en) * 2006-03-01 2007-09-13 Dr. Reddy's Laboratories Ltd. Polymorphic forms of rimonabant
JP2009539869A (ja) * 2006-06-06 2009-11-19 スレショルド ファーマシューティカルズ インコーポレイティッド グルフォスファミドの単位用量形態
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
EP2535058A3 (en) * 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
ATE482961T1 (de) 2008-04-25 2010-10-15 Sandoz Ag Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
US9393201B2 (en) 2009-09-21 2016-07-19 Jw Pharmaceutical Corporation Oxaliplatin nanoparticles and method for preparing same
WO2011101865A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
DK2568987T3 (en) 2010-05-12 2017-02-20 Rempex Pharmaceuticals Inc Tetracycline COMPOSITIONS
US8861919B2 (en) 2011-02-16 2014-10-14 Tyco Electronics Corporation Fiber optic closure
JP6161593B2 (ja) 2011-04-15 2017-07-12 ヤンセン ファーマシューティカ エヌ．ベー． 凍結乾燥された薬物ナノ懸濁物
CN103230371B (zh) * 2012-05-18 2014-07-23 湖北一半天制药有限公司 注射用奥沙利铂冻干制剂的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106706785B (zh) * 2016-12-23 2019-02-26 东药集团沈阳施德药业有限公司 一种采用高效液相色谱检测厄贝沙坦氢氯噻嗪片中有关物质的方法
US10149857B2 (en) 2017-03-09 2018-12-11 Ampac Fine Chemicals Llc Lyophilized cyclophosphamide composition and methods of preparation thereof
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CA3084369A1 (en) * 2017-12-07 2019-06-13 Reven, Llc Compositions and methods for the treatment of metabolic conditions
US20230059869A1 (en) 2021-08-03 2023-02-23 Liqmeds Worldwide Limited Oral pharmaceutical solution of clopidogrel
CN114533683B (zh) * 2021-12-23 2023-08-01 李宏 一种注射用腺苷钴胺冻干制剂组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS532931B2 (pt) * 1973-12-05 1978-02-01
GB2021581B (en) * 1978-05-17 1982-10-20 Wellcome Found Stabilisation of pgl derivatives
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
CA2013474C (en) * 1989-04-20 2000-01-18 Pharmacia Inc. Cyclophosphamide - alanine lyophilizates
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
IL105553A (en) * 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.

Also Published As

Publication number Publication date
NO981967D0 (no) 1998-04-30
TR199800782T2 (xx) 1998-09-21
NO322582B1 (no) 2006-10-30
EE9800123A (et) 1998-10-15
ES2180805T3 (es) 2003-02-16
DE69622735T2 (de) 2003-04-03
JPH11507945A (ja) 1999-07-13
AU713383B2 (en) 1999-12-02
CN1124844C (zh) 2003-10-22
EP0858325B1 (fr) 2002-07-31
AR004255A1 (es) 1998-11-04
SK52598A3 (en) 1998-10-07
US6284277B1 (en) 2001-09-04
TW442295B (en) 2001-06-23
NZ321616A (en) 1999-04-29
DE69622735D1 (de) 2002-09-05
SK283031B6 (sk) 2003-02-04
CZ287178B6 (en) 2000-10-11
CA2234140C (fr) 2004-10-26
EP0858325A1 (fr) 1998-08-19
PT858325E (pt) 2002-12-31
AU7499096A (en) 1997-05-29
WO1997017064A1 (fr) 1997-05-15
PL186284B1 (pl) 2003-12-31
IS1967B (is) 2004-12-15
IS4729A (is) 1998-04-29
CN1203527A (zh) 1998-12-30
UA60297C2 (uk) 2003-10-15
CA2234140A1 (fr) 1997-05-15
IL124214A (en) 2001-01-28
MX9803344A (es) 1998-09-30
FR2740686A1 (fr) 1997-05-09
KR100367752B1 (ko) 2003-03-15
PL326451A1 (en) 1998-09-28
HK1015697A1 (en) 1999-10-22
FR2740686B1 (fr) 1998-01-16
KR19990067325A (ko) 1999-08-16
ATE221374T1 (de) 2002-08-15
MY116578A (en) 2004-02-28
ZA969176B (en) 1998-04-30
CZ123198A3 (cs) 1998-07-15
JP3357376B2 (ja) 2002-12-16
EE04293B1 (et) 2004-06-15
NO981967L (no) 1998-06-30
DK0858325T3 (da) 2002-11-25
RU2163801C2 (ru) 2001-03-10

Similar Documents

Publication Publication Date Title
BR9611367A (pt) Formulação farmacêutic liofilizada estável
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
ID24654A (id) Formulasi farmasi omeprazola
DE69525148D1 (de) Pharmazeutische formulierung
NO20004345L (no) Farmasøytisk sammensetning
BR9610396A (pt) Formulação farmacêutica
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
DE69614407D1 (de) Pharmazeutische zusammensetzungen
ID16781A (id) Formulasi-formulasi farmasi
LV11727A (lv) Farmaceitiska kompozicija
ITMI941169A0 (it) Formulazioni farmaceutiche
FI973280A0 (fi) Farmaseuttinen koostumus
FI973230A (fi) Uusi farmaseuttinen formulaatio
BR9606066A (pt) Composto e formulação farmacêutica
BR9605777A (pt) Composição farmacêutica
NO964309D0 (no) Farmasöytisk sammensetning
SE9600141D0 (sv) Pharmaceutical formulation
HUP9900016A3 (en) Stable freeze-dried pharmaceutical formulation
DE29618094U1 (de) Pharmazeutisches Präparat
SE9502453D0 (sv) Drug formulations

Legal Events

Date Code Title Description
TE Change of address
PC Transfer

Free format text: SANOFI SYNTHELABO (FR)

EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/06/2008, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061553/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132273-17.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:OSI PHARMACEUTICALS, LLC , PFIZER, SANOFI-AVERTI, , SANOFI-AVERTI DEUTCHLAND GMBH, SCHERING CORPORATION.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130004258, DE 11/10/2013